In vivo human time-exposure study of orally dosed commercial silver nanoparticles Mark A. Munger, PharmD, Przemyslaw Radwanski, PharmD, PhD, Greg C. Hadlock, PhD, Greg Stoddard, MS, Akram Shaaban, MD, Jonathan Falconer, BS, David W. Grainger, PhD, Cassandra E. Deering-Rice, PhD Nanomedicine: Nanotechnology, Biology and Medicine Volume 10, Issue 1, Pages 1-9 (January 2014) DOI: 10.1016/j.nano.2013.06.010 Copyright © 2014 Elsevier Inc. Terms and Conditions
Figure 1 Optical absorbance spectrum of 32ppm commercial AgNPs measured on samples taken directly from the study stock bottle used in human oral ingestion and exposures (lot # 09280). Nanomedicine: Nanotechnology, Biology and Medicine 2014 10, 1-9DOI: (10.1016/j.nano.2013.06.010) Copyright © 2014 Elsevier Inc. Terms and Conditions
Figure 2 Dynamic Light Scattering (DLS) particle size characterization of 32ppm commercial AgNPs as taken directly from commercial silver nanoparticle sample (lot # 09280). Nanomedicine: Nanotechnology, Biology and Medicine 2014 10, 1-9DOI: (10.1016/j.nano.2013.06.010) Copyright © 2014 Elsevier Inc. Terms and Conditions
Nanomedicine: Nanotechnology, Biology and Medicine 2014 10, 1-9DOI: (10.1016/j.nano.2013.06.010) Copyright © 2014 Elsevier Inc. Terms and Conditions